Loading clinical trials...
Loading clinical trials...
The Headache-inducing Effects of Levcromakalim in Patients With Cluster Headache
Cluster headache is a primary headache disorder characterized by attacks of unilateral headache of short duration and severe pain intensity. There is an unmet need to understand the underlying disease mechanisms that will ultimately lead to the development of disease-specific medicines. Until now, it has been suggested that the calcitonin gene-related peptide (CGRP) plays a major role in the initiation of a cluster headache attack, possibly involving the ATP-sensitive potassium channels. The current study aims to determine whether the opening of ATP-sensitive potassium channels triggers cluster headache attacks in patients with cluster headache.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Danish Headache Center
Glostrup Municipality, Copenhagen, Denmark
Start Date
June 4, 2021
Primary Completion Date
September 27, 2022
Completion Date
September 27, 2022
Last Updated
June 28, 2023
41
ACTUAL participants
Levcromakalim
DRUG
Saline
DRUG
Lead Sponsor
Danish Headache Center
NCT04939922
NCT07370142
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06841627